)
Aurobindo Pharma is trading higher by 3% at Rs 1,032 on NSE after reporting a robust 58% year on year (yoy) jump in consolidated net profit at Rs 372 crore for the second quarter ended September 2014 (Q2), mainly on account of overall growth led by US Generics. The drug maker had profit of Rs 235 crore in a year ago quarter.
Consolidated net operating income in July-September quarter grew by 50% to Rs 2,881 crore against Rs 1,914 crore in the corresponding quarter of previous fiscal.
EBITDA or operating profit margin however, declined to 22.1% from 22.9% during the recently concluded quarter.
“The EBITDA during the quarter on Y-o-Y basis has declined by 79bps due to increase in staff cost and other expenses to net operating income by 1.5% and 3.4% respectively, offset by decrease in materials consumptions to net operating income by 4.1% as a result of improved business mix,” Aurobindo Pharma said in a statement.
The stock opened at Rs 1,002 and hit a new high of Rs 1,039 on NSE. A combined 1.7 million shares changed hands on the counter till 1050 hours on NSE and BSE.
Consolidated net operating income in July-September quarter grew by 50% to Rs 2,881 crore against Rs 1,914 crore in the corresponding quarter of previous fiscal.
EBITDA or operating profit margin however, declined to 22.1% from 22.9% during the recently concluded quarter.
“The EBITDA during the quarter on Y-o-Y basis has declined by 79bps due to increase in staff cost and other expenses to net operating income by 1.5% and 3.4% respectively, offset by decrease in materials consumptions to net operating income by 4.1% as a result of improved business mix,” Aurobindo Pharma said in a statement.
The stock opened at Rs 1,002 and hit a new high of Rs 1,039 on NSE. A combined 1.7 million shares changed hands on the counter till 1050 hours on NSE and BSE.
